CNS-Teva, Other (87 288 890 ou 87 795 131)
Teva and MedinCell Announce FDA Acceptance of New Drug Application for TV-46000/mdc-IRM as a Treatment for Patients with Schizophrenia | Business Wire
2012 EDITION - Teva Pharmaceuticals
Teva Pharmaceuticals - Wikipedia
Central Nervous System Is Key to Teva's Specialty Medicines
The ALS Association, Huntington's Disease Society of America, and Teva Pharmaceuticals Launch Teva CNS Target Identification Challenge - The ALS Association
Teva Pharmaceuticals and IBM Expand Global Partnership to Enable Drug Development and Chronic Disease Management with
Teva Pharmaceuticals: Key Facts And Trends Of 2015-2016 (NYSE:TEVA) | Seeking Alpha
Teva pharmaceutical industries limited
Teva uses social media to promote their research challenge -
Teva, IBM to tackle new drugs, chronic diseases with AI | The Times of Israel
Teva pharmaceutical industries limited
Teva to strengthen CNS portfolio with Auspex acquisition | Drug Store News
ADDING MULTIMEDIA Teva Announces U.S. Approval of AJOVYTM (fremanezumab-vfrm) Injection, the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Preventive Treatment of Migraine in Adults | Business
Teva closes Paragard sale to CooperSurgical - MassDevice
How TEVA's CNS Drugs Performed in 1H17
Teva Pharmaceuticals / Annual Report on Behance
Teva Canada Announces New Autoinjector for AJOVY® for the Preventive Treatment of Migraine in Adults | Business Wire
Teva makes $40B offer for Mylan
Teva Pharmaceuticals: a leader in CNS specialty medicine
